Archivio istituzionale della ricerca dell'Università degli Studi di Palermo
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, pubblicazioni, progetti, attività) adottato dall’Università di Palermo, e ha lo scopo di raccogliere, conservare, documentare, e diffondere ad accesso aperto le informazioni relative alla produzione scientifica degli autori afferenti all’Ateneo.
EnglishPsoriasis and psoriatic arthritis are common diseases associated with considerable morbidity and disability. Their pathophysiology comprises similar processes leading to inflammation of skin, entheses, and joints. Although traditional systemic agents can be effective, their use may be limited by lack of efficacy and concerns regarding adverse effects. The objective of this study was to assess the efficacy and safety of adalimumab, a fully human antitumor necrosis factor (anti-TNF) monoclonal antibody, over 16 weeks. The present authors report their personal experience in 15 patients with severe plaque psoriasis and psoriatic arthritis, refractory to other treatments, in which a decisive regression of joint/skin involvement was obtained. Psoriasis and psoriatic arthritis are chronic inflammatory disorders resulting from a combination of genetic and environmental factors.
Bongiorno, M., Pistone, G., Doukaki, S., & Arico', M. (2008). Adalimumab For Treatment Of Moderate–Severe Psoriasis And Psoriatic Arthritis. DERMATOLOGIC THERAPY, 21(Suppl. 2), S15-S20 [10.1111/j.1529-8019.2008.00227.x].
| Data di pubblicazione: | 2008 | |
| Titolo: | Adalimumab For Treatment Of Moderate–Severe Psoriasis And Psoriatic Arthritis | |
| Autori: | ||
| Citazione: | Bongiorno, M., Pistone, G., Doukaki, S., & Arico', M. (2008). Adalimumab For Treatment Of Moderate–Severe Psoriasis And Psoriatic Arthritis. DERMATOLOGIC THERAPY, 21(Suppl. 2), S15-S20 [10.1111/j.1529-8019.2008.00227.x]. | |
| Rivista: | ||
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1111/j.1529-8019.2008.00227.x | |
| Abstract: | Psoriasis and psoriatic arthritis are common diseases associated with considerable morbidity and disability. Their pathophysiology comprises similar processes leading to inflammation of skin, entheses, and joints. Although traditional systemic agents can be effective, their use may be limited by lack of efficacy and concerns regarding adverse effects. The objective of this study was to assess the efficacy and safety of adalimumab, a fully human antitumor necrosis factor (anti-TNF) monoclonal antibody, over 16 weeks. The present authors report their personal experience in 15 patients with severe plaque psoriasis and psoriatic arthritis, refractory to other treatments, in which a decisive regression of joint/skin involvement was obtained. Psoriasis and psoriatic arthritis are chronic inflammatory disorders resulting from a combination of genetic and environmental factors. | |
| Settore Scientifico Disciplinare: | Settore MED/35 - Malattie Cutanee E Veneree | |
| Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| Bongiorno_et_al-2008-Dermatologic_Therapy.pdf | N/A | Administrator Richiedi una copia |
Copyright © 2022